Safety and immunogenicity of a glycoprotein D genital herpes vaccine in healthy girls 10-17 years of age: results from a randomised, controlled, double-blind trial.
Vaccine
; 31(51): 6136-43, 2013 12 09.
Article
in En
| MEDLINE
| ID: mdl-23850416
Key words
(S)AE; (serious) adverse event; 95% CI; 95% confidence interval; AS04; ATP; Alum; ELISA; ELISA units; EU; GMC; GSK; Genital herpes; GlaxoSmithKline; HAV; HSV; HSV vaccine; HSV-1; HSV-2; Herpes simplex virus type 1; Herpes simplex virus type 2; IU; IgG; MPL; NOCD; OD; Safety; TVC; according to protocol; aluminium hydroxide; aluminium hydroxide and 3-O-deacylated monophosphoryl lipid A adjuvant system; enzyme-linked immunosorbent assay; gD2; geometric mean concentration; hepatitis A vaccine; herpes simplex virus; herpes simplex virus type 1; herpes simplex virus type 2; herpes simplex virus type 2 glycoprotein D; immunoglobulin G; international units; monophosphoryl lipid A; new onset chronic diseases; optical density; total vaccinated cohort
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Herpes Genitalis
/
Herpesvirus Vaccines
/
Drug-Related Side Effects and Adverse Reactions
Type of study:
Clinical_trials
Limits:
Adolescent
/
Child
/
Female
/
Humans
Language:
En
Journal:
Vaccine
Year:
2013
Document type:
Article
Country of publication:
Países Bajos